Company intelligence / Profile preview
Tianjin Conjustar Biotechnology Co., Ltd.
Tianjin, Tianjin, Chinacrunchbase.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Tianjin Conjustar has advanced two main peptide-drug conjugate oncology assets into Phase 1 clinical trials in China, targeting solid tumors and neoplasms. SC‑101 received IND approval from both China's NMPA and the US FDA in 2024, while SC‑102 entered Phase I trials for metastatic solid tumors. The company is developing a total of five oncology pipeline programs with a focus on improving drug delivery and efficacy over existing ADC therapies. No published late-stage or pivotal results as of May 2025.
- Therapeutic areas
- Oncology
- Modalities
- Antibody-drug conjugates (ADC)Peptide-drug conjugates (PDC)Chemical drugs
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
Incubated by Fosun Health Capital New Drug FundWuXi AppTec
Beyond the preview
Go deeper on Tianjin Conjustar Biotechnology Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tianjin Conjustar Biotechnology Co., Ltd..